U.S. Markets closed

Repare Therapeutics Inc. (RPTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
31.50+0.85 (+2.77%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close30.65
Open30.37
Bid29.01 x 900
Ask34.05 x 800
Day's Range30.10 - 32.31
52 Week Range21.76 - 46.44
Volume283,368
Avg. Volume128,933
Market Cap1.165B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar 04, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est46.71
  • Business Wire

    Repare Therapeutics Appoints Thomas Civik to Its Board and as New Chairman

    CAMBRIDGE, Mass. & MONTREAL, September 07, 2021--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Thomas Civik to its Board of Directors and as its Chairman. He replaces Jerel Davis, Ph.D., Managing Director at Versant Ventures, who will remain a member of the Company’s Board.

  • Business Wire

    Repare Therapeutics to Participate at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference

    CAMBRIDGE, Mass. & MONTREAL, September 02, 2021--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in a fireside chat at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on Thursday, September 9 at 2:45 p.m. Eastern Time.

  • Business Wire

    Repare Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

    CAMBRIDGE, Mass. & MONTREAL, August 12, 2021--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the second quarter ended June 30, 2021.